PE20141030A1 - Cristal de compuesto heterociclico fusionado - Google Patents

Cristal de compuesto heterociclico fusionado

Info

Publication number
PE20141030A1
PE20141030A1 PE2013002859A PE2013002859A PE20141030A1 PE 20141030 A1 PE20141030 A1 PE 20141030A1 PE 2013002859 A PE2013002859 A PE 2013002859A PE 2013002859 A PE2013002859 A PE 2013002859A PE 20141030 A1 PE20141030 A1 PE 20141030A1
Authority
PE
Peru
Prior art keywords
heterocyclic compound
fused heterocyclic
compound crystal
imidazo
pyridin
Prior art date
Application number
PE2013002859A
Other languages
English (en)
Inventor
Katsuhiko Yamamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20141030A1 publication Critical patent/PE20141030A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A UN CRISTAL DE FORMULA 1-ETIL-7-METIL-3-{4-[(3-METIL-3H-IMIDAZO[4,5-B]PIRIDIN-2-IL)OXI]FENIL}-1,3-DIHIDRO-2H-IMIDAZO[4,5-B]PIRIDIN-2-ONA CARACTERIZADO PORQUE MUESTRA UN PATRON DE DIFRACCION DE POLVO POR RAYOS X CON PICOS CARACTERISTICOS EN ESPACIAMIENTOS INTERPLANARES DE 13,59�0,2 Y 6,76�0,2 ANGSTROMS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN INHIBIDOR DE LA FOSFODIESTERASA 10A, SIENDO UTIL EN EL TRATAMIENTO DE LA ESQUIZOFRENIA.
PE2013002859A 2011-06-22 2012-06-21 Cristal de compuesto heterociclico fusionado PE20141030A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011138920 2011-06-22

Publications (1)

Publication Number Publication Date
PE20141030A1 true PE20141030A1 (es) 2014-08-29

Family

ID=46551819

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002859A PE20141030A1 (es) 2011-06-22 2012-06-21 Cristal de compuesto heterociclico fusionado

Country Status (26)

Country Link
US (1) US9512118B2 (es)
EP (1) EP2723738B1 (es)
JP (1) JP6025757B2 (es)
KR (1) KR20140040777A (es)
CN (1) CN103608348B (es)
AR (1) AR087004A1 (es)
AU (1) AU2012274292B2 (es)
BR (1) BR112013032052A2 (es)
CA (1) CA2839825C (es)
CL (1) CL2013003632A1 (es)
CO (1) CO6862150A2 (es)
CR (1) CR20140033A (es)
DO (1) DOP2013000311A (es)
EA (1) EA026137B1 (es)
EC (1) ECSP14013165A (es)
GE (1) GEP20166475B (es)
MA (1) MA35274B1 (es)
MX (1) MX342990B (es)
MY (1) MY163483A (es)
PE (1) PE20141030A1 (es)
TN (1) TN2013000510A1 (es)
TW (1) TWI570122B (es)
UA (1) UA112082C2 (es)
UY (1) UY34150A (es)
WO (1) WO2012176934A1 (es)
ZA (1) ZA201309611B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012124782A1 (ja) * 2011-03-16 2012-09-20 武田薬品工業株式会社 縮合複素環化合物
US10308626B1 (en) 2018-07-02 2019-06-04 Pratt Bethers Crystal purification in a glass or metal container
US10960322B2 (en) 2018-07-02 2021-03-30 Pratt Bethers Apparatus for purifying crystals using solvent vapors
US10851076B2 (en) 2017-08-10 2020-12-01 Pratt Bethers Method for purifying crystals using solvent vapors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
WO2006038111A1 (en) * 2004-10-07 2006-04-13 Pfizer Products Inc. Benzoimidazole derivatives useful as antiproliferative agents
JP5220414B2 (ja) 2005-08-30 2013-06-26 旭化成ファーマ株式会社 スルホンアミド化合物
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
JP5175228B2 (ja) * 2006-02-15 2013-04-03 サノフイ 新規なアザシクリル置換アリールジヒドロイソキノリノン、それらの製造方法及び薬剤としてそれらの使用
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
KR101524817B1 (ko) 2007-04-18 2015-06-01 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 축합환 유도체, 그것을 함유하는 의약 조성물 및 그 의약 용도
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
AR074343A1 (es) 2008-11-14 2011-01-12 Amgen Inc Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶10抑制劑之吡衍生物
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
BR112012032087A2 (pt) * 2010-06-24 2016-11-16 Takeda Pharmaceuticals Co composto, medicamento, e, uso de um composto
EP2601192B1 (en) 2010-08-04 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP2604597B1 (en) 2010-08-10 2017-01-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a
WO2012124782A1 (ja) 2011-03-16 2012-09-20 武田薬品工業株式会社 縮合複素環化合物

Also Published As

Publication number Publication date
GEP20166475B (en) 2016-05-10
EP2723738A1 (en) 2014-04-30
TW201313709A (zh) 2013-04-01
CN103608348A (zh) 2014-02-26
CR20140033A (es) 2014-03-12
UY34150A (es) 2013-01-31
AR087004A1 (es) 2014-02-05
CL2013003632A1 (es) 2014-06-06
ECSP14013165A (es) 2014-02-28
EP2723738B1 (en) 2018-03-14
ZA201309611B (en) 2014-08-27
JP6025757B2 (ja) 2016-11-16
TN2013000510A1 (en) 2015-03-30
WO2012176934A1 (en) 2012-12-27
CN103608348B (zh) 2016-03-30
MX342990B (es) 2016-10-20
EA201490092A1 (ru) 2014-05-30
KR20140040777A (ko) 2014-04-03
AU2012274292A1 (en) 2014-01-16
MX2013015354A (es) 2014-02-11
EA026137B1 (ru) 2017-03-31
NZ618944A (en) 2015-08-28
TWI570122B (zh) 2017-02-11
UA112082C2 (uk) 2016-07-25
JP2014516918A (ja) 2014-07-17
US20140113932A1 (en) 2014-04-24
DOP2013000311A (es) 2014-02-28
US9512118B2 (en) 2016-12-06
CA2839825A1 (en) 2012-12-27
MY163483A (en) 2017-09-15
AU2012274292B2 (en) 2016-10-27
CA2839825C (en) 2019-04-09
CO6862150A2 (es) 2014-02-10
MA35274B1 (fr) 2014-07-03
BR112013032052A2 (pt) 2016-12-13

Similar Documents

Publication Publication Date Title
PE20130346A1 (es) Compuestos heterociclicos fusionados
NZ716420A (en) Fused heterocyclic compounds as sodium channel modulators
CR20120277A (es) Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa
AR078766A1 (es) Formas solidas de n-(4-(7-azabiciclo(2.2.1) heptan-7-il)-2-( trifluorometil) fenil)-4-oxo-5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
CO6251357A2 (es) Nuevos derivados de acido azabifenilaminobenzoico
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
NZ602311A (en) Anti-infective compounds
UY32606A (es) Sulfonamidas nematocidas
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
PE20141540A1 (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
PE20090511A1 (es) Imidazopiridinonas
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
RS53179B (en) BENZODIAZEPINSKI INHIBITOR BROMODOMENA
PE20140970A1 (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazol [3,4-d) pirimidin-4-ona y su uso como inhibidores de pde9a
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
ECSP088456A (es) Derivados de [4-(benzo[b]tiofen-2-il)pirimidn-2il]-amina como inhibidores ikk-beta para el tratamiento de cancer y enfermedades inflamatorias
PE20130184A1 (es) Compuesto heterociclico
UY32432A (es) Compuestos de pirimidina fusionada como inhibidores de akt
NZ701894A (en) Dimethyl-benzoic acid compounds
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
NZ594403A (en) Amorphous salt of a macrocyclic inhibitor of hcv
PE20141030A1 (es) Cristal de compuesto heterociclico fusionado

Legal Events

Date Code Title Description
FC Refusal